Celcuity Inc

CELC remains in a Stage 4 decline with a clear sequence of lower highs and lower lows reinforced by a bearish primary pattern. Medium-term bias is bearish, but near-term price is extended below declining EMAs and oversold, offering no optimal Sell Now setup. Execution is deferred: plan to Trim into any relief bounce into the 9/20 EMA and 50 DMA confluence for higher-probability entries.

• ↑Phase III Victoria I trial reported 9.3-month median PFS for gadotelicib.
• ↑FDA PDUFA date set for July 17, 2026; management sees no delay risk.
• ↓Q1 2026 net loss rose to $52.8M vs $37M last year.